Compound ID | 3399
VRELysin
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Direct acting; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-positive |
| Target Pathogen: | Active against vancomycin-resistant Enterococcus sp.; intended indication for vancomycin-resistant enterococcus bacteraemia and gastrointestinal tract infection |
| Institute where first reported: | Intralytix |
| Year first mentioned: | 2023 |
| Highest development stage: | Phase 2 (NCT05715619) |
| Development status: | Active |
| External links: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.